Dr. Ruben Mesa on Late-Stage Trials in Myelofibrosis
Ruben A. Mesa, MD
Published Online: Monday, April 15, 2013
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.
Pomalidomide will be compared to placebo to determine the true benefit of the drug for anemia. Pomalidomide may be active on its own or it may prove to be a natural complement to JAK2 inhibitor therapy, according to Mesa.
Another phase III study will examine the efficacy of SAR302503 in comparison to placebo.
Data from parallel phase II combination studies will examine ruxolitinib in combination with agents to help inhibit fibrosis, improve anemia, or target downstream pathways of JAK2.
New data and upcoming trial make it an exciting time for the treatment of myeloproliferative neoplasms, Mesa says.
Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options
As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.